Placebo ELLIPTA

DRUG3 trials

Sponsors

Hospital General Universitario Gregorio Maranon, GlaxoSmithKline

Conditions

Chronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50%Pulmonary Disease, Chronic Obstructive

Phase 2

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

TerminatedNCT03345407

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2017-11-28End: 2019-01-10Updated: 2021-07-14

Phase 4

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT02982187

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2016-12-30End: 2017-06-19Updated: 2019-10-21

Phase IV, single-center, double blind, randomized, crossover, placebo-controlled study, to investigate the effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure

Not yet recruitingCTIS2024-519513-61-00

Hospital General Universitario Gregorio MaranonChronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50%

Target: 60Updated: 2024-11-20